Leishmaniasis and vaccine development: current progress, challenges, and future perspectives.
- 1Acharya Prafulla Chandra Roy Government College, Siliguri, West Bengal, India.
- 2Post Graduate Department of Zoology, Barasat Government College, Barasat, West Bengal, India.
- 3Institute of Health Sciences, Presidency University, New Town, West Bengal, India.
Abstract
Leishmaniasis remains one of the most important neglected tropical diseases (NTDs), affecting millions of individuals across tropical and subtropical regions. Caused by protozoan parasites of the genus Leishmania and transmitted by infected female phlebotomine sandflies, the disease manifests in a spectrum of clinical forms ranging from localized cutaneous lesions to fatal visceral infections. Despite substantial progress in disease control programmes, leishmaniasis continues to pose significant public health, socioeconomic, and healthcare challenges in endemic countries. Current chemotherapeutic options, including pentavalent antimonials, amphotericin B formulations, miltefosine, paromomycin, and pentamidine, are constrained by toxicity, prolonged treatment regimens, high costs, and the emergence of drug-resistant parasite strains. Moreover, the absence of a licensed human vaccine remains a major obstacle to sustainable disease control. Consequently, the development of effective vaccines has emerged as a major research priority. Advances in molecular parasitology, immunology, and vaccine technology have led to the development of first-generation killed and live-attenuated vaccines, second-generation recombinant protein and subunit vaccines, and third-generation nucleic acid-based vaccine platforms. Recent innovations involving mRNA vaccines, viral vectors, genetically attenuated parasites, and controlled human infection models have further accelerated translational research. In parallel, advances in genomics, immunoinformatics, artificial intelligence, and nanotechnology are facilitating the identification of novel therapeutic targets, vaccine antigens, and precision intervention strategies. Nevertheless, the complex biology of Leishmania, antigenic diversity, and sophisticated immune-evasion mechanisms continue to impede vaccine licensure. This review discusses the global burden of leishmaniasis, host-parasite interactions, current therapeutic approaches, mechanisms of drug resistance, vaccine development strategies, and emerging technologies that are shaping the future of leishmaniasis prevention and treatment.
Related
- Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development.
- Clinical challenges in vaccine and monoclonal antibody development against ESCAPE pathogens: insights from EMA scientific advice procedures.
- Application Value and Cognitive Challenges of PET/CT in the Diagnosis and Treatment of Visceral Leishmaniasis: A Retrospective Single-Center Case Series and Literature Review
- Autophagy in Silkworm Biology: Progress and Perspectives.
- The application value of artificial intelligence in medical imaging: foundations, progress, and challenges.
BibTeX
@article{dey2026leishmaniasis,
title = {{Leishmaniasis and vaccine development: current progress, challenges, and future perspectives.}},
author = {Somaditya Dey and Anushka Ghosh and Debarati Mukherjee},
journal = {Frontiers in cellular and infection microbiology},
year = {2026},
month = oct,
doi = {10.3389/fcimb.2026.1929424},
url = {https://europepmc.org/article/MED/42923154},
note = {CC BY},
}
RIS
TY - JOUR
TI - Leishmaniasis and vaccine development: current progress, challenges, and future perspectives.
AU - Somaditya Dey
AU - Anushka Ghosh
AU - Debarati Mukherjee
PY - 2026
DA - 2026/10/08
JO - Frontiers in cellular and infection microbiology
DO - 10.3389/fcimb.2026.1929424
UR - https://europepmc.org/article/MED/42923154
AB - Leishmaniasis remains one of the most important neglected tropical diseases (NTDs), affecting millions of individuals across tropical and subtropical regions. Caused by protozoan parasites of the genus Leishmania and transmitted by infected female phlebotomine sandflies, the disease manifests in a spectrum of clinical forms ranging from localized cutaneous lesions to fatal visceral infections. Despite substantial progress in disease control programmes, leishmaniasis continues to pose significant public health, socioeconomic, and healthcare challenges in endemic countries. Current chemotherapeutic options, including pentavalent antimonials, amphotericin B formulations, miltefosine, paromomycin, and pentamidine, are constrained by toxicity, prolonged treatment regimens, high costs, and the emergence of drug-resistant parasite strains. Moreover, the absence of a licensed human vaccine remains a major obstacle to sustainable disease control. Consequently, the development of effective vaccines has emerged as a major research priority. Advances in molecular parasitology, immunology, and vaccine technology have led to the development of first-generation killed and live-attenuated vaccines, second-generation recombinant protein and subunit vaccines, and third-generation nucleic acid-based vaccine platforms. Recent innovations involving mRNA vaccines, viral vectors, genetically attenuated parasites, and controlled human infection models have further accelerated translational research. In parallel, advances in genomics, immunoinformatics, artificial intelligence, and nanotechnology are facilitating the identification of novel therapeutic targets, vaccine antigens, and precision intervention strategies. Nevertheless, the complex biology of Leishmania, antigenic diversity, and sophisticated immune-evasion mechanisms continue to impede vaccine licensure. This review discusses the global burden of leishmaniasis, host-parasite interactions, current therapeutic approaches, mechanisms of drug resistance, vaccine development strategies, and emerging technologies that are shaping the future of leishmaniasis prevention and treatment.
SN - 2235-2988
ER -